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Abstract 
Membrane extrusion was investigated for predicting the stability of soya 
phosphatidylcholine liposomes and surfactosomes (Tween 80-enriched liposomes) to 
nebulization. Formulations were prepared with or without cholesterol, and salbutamol 
sulphate (SBS) or beclometasone dipropionate (BDP) were incorporated as model 
hydrophilic or hydrophobic drugs respectively. Formulations were extruded through 5, 2, 1 
and 0.4 µm polycarbonate membrane filters to study the influence of membrane pore size on 
drug retention by the vesicles. Surfactosomes were found to be very leaky to SBS; such that 
even without extrusion greater than 50% of the originally entrapped drug was lost, and 
cholesterol minimized drug losses. The smaller the pore size, the greater the leakage of SBS; 
hence only around 10% were retained in cholesterol-free surfactosomes extruded through 
0.4 µm filters. To study the influence of vesicle size on SBS retained entrapment, an 
excessive extrusion protocol was proposed (51 extrusion cycles through 1 µm filters) to 
compare the stability of freshly prepared vesicles (i.e. unextruded; approx. 4.5-6.5 µm) with 
those previously extruded through 1 µm pores. Cholesterol was essential for minimizing 
losses from liposomes, whilst for surfactosomes size reduction prior to extrusion was the 
only way to minimize SBS losses which reached up to 93.40% of the originally entrapped 
drug when no cholesterol was included. When extrusion was applied to BDP-loaded 
vesicles, greater proportions of the drug were retained in the vesicles compared to SBS. 
Even with extrusion through 0.4 µm, BDP retention was around 50-60% with little effect of 
formulation. Excessive extrusion showed BDP retention using small liposomes (1µm) to be 
as high as 71-87%, compared to 50-66% for freshly prepared vesicles. The findings, based 
on extrusion, were compared to studies of vesicle stability to nebulization, published by a 
range of investigators. It was concluded that extrusion is a valid method for predicting the 
stability of liposomes to nebulization.   
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1. Introduction 
Inhalation of liposomal drug formulations via nebulization can prolong drug residence 
within the lung, potentially maximizing therapeutic benefit, whilst reducing systemic 
adverse effects (Taylor et al., 1989; Saari et al., 1999; Fauvel et al., 2012; Gaspar et al., 
2012; Cipolla et al., 2013; Clancy et al., 2013). However, damage of the liposome structures 
during air-jet nebulization can cause loss of the originally entrapped material; thus liposome 
stability to nebulization-induced damage should be considered (Taylor et al., 1990b; Niven 
et al., 1991; Elhissi et al., 2006a; Elhissi et al., 2007; Chadha et al., 2012; Nasr et al., 2013). 
Loss of entrapped hydrophilic agent can be minimized by reducing liposome size before jet-
nebulization (Taylor et al., 1990b; Niven et al., 1991) or by inclusion of cholesterol (Taylor 
et al., 1990b; Tseng et al., 2007; Chadha et al., 2012) or high phase transition phospholipid 
(Niven and Schreier, 1990).  
 
Vibrating-mesh nebulizers have revolutionized pulmonary delivery of conventional 
solutions (Dhand, 2002) and novel drug delivery systems, such as liposomes (Elhissi and 
Taylor, 2005; Kleemann et al., 2007; Nasr et al., 2013; Cipolla et al., 2014; Lehofer et al., 
2014). Compared to air-jet nebulizers, vibrating-mesh devices may cause less damage to 
liposomal structures and hence higher proportions of the originally entrapped hydrophilic 
drug can be retained during aerosolization (Elhissi et al., 2006a; Elhissi et al., 2007), 
especially when the vesicles are extruded to the size of 1 µm prior to nebulization, and by 
using devices with large mesh apertures (Elhissi et al., 2007). Arikace® (Insmed, NJ, USA), 
a novel nebulizable liposome formulation of the hydrophilic anti-pseudomonal antibiotic 
amikacin is currently in phase III trials, and has been demonstrated to be well tolerated by 
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cystic fibrosis patients, with prolonged drug residence in the lung and enhanced penetration 
through pseudomonas aeruginosa biofilms. The success of this formulation has been 
attributed to the use of appropriate formulation (cholesterol-enriched 
dipalmitoylphosphatidylcholine with vesicle size around 300 nm) and suitable inhalation 
device (Pari e-Flow mesh nebulizer) (Clancy et al., 2013; Ehsan et al., 2014; Waters and 
Ratjen, 2014). 
 
Unlike hydrophilic drugs, the loss of hydrophobic materials (e.g. steroids) from liposomes 
during nebulization is dependent on lipid bilayer composition and mode of drug interaction 
with the bilayers (Darwis and Kellaway, 2001; Elhissi et al., 2006b). For example, 
beclometasone dipropionate (BDP) inhaled in liposomes showed prolonged retention in the 
respiratory tract of human volunteers, although liposomes underwent marked size reduction 
during jet-nebulization from 3.49 to 0.83 µm and from 5.07 to 0.91 µm for 
dilauroylphosphatidylcholine (DLPC; a low Tm phospholipid) and 
dipalmitoylphosphatidylcholine liposomes (DPPC; a high Tm phospholipid) respectively 
(Saari et al., 1999). Hence, size reduction (i.e. massive disruption) of the liposomes during 
nebulization did not cause marked loss of the entrapped BDP. These findings are consistent 
with in vitro studies using BDP (Elhissi et al., 2011) and other hydrophobic drugs, such as 
ciprofloxacin (Desai et al., 2002). Clinical trials have been conducted with Pulmaquin™ 
(Aradigm Corp., CA, USA), a nebulizable liposomal formulation of ciprofloxacin for 
inhalation by non-cystic fibrosis bronchiectasis patients (Cipolla et al., 2013; Serisier et al., 
2013). 
 
Studies investigating the physical stability of liposomes during nebulization are usually 
conducted using nebulizers linked with appropriate aerosol collection systems (e.g. 
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impingers or impactors), followed by analysis to determine drug losses from aerosolized 
liposomes (Taylor et al., 1990b; Desai et al., 2002; Elhissi et al., 2007; Kamalaporn et al., 
2014). This approach is laborious and time-consuming, and loss of aerosol to the 
surrounding environment is a potential hazard, even with standard aerosol-collection 
models. It has been reported that aerosolized particles to impingers may bounce from the 
bottom of the collection compartment or be re-aerosolized with liquid bubbles created by 
the air flowing into the impinge, causing particles to escape with the effluent air, resulting in 
reduced aerosol collection efficiency (Grinshpun et al., 2007). Moreover, hydrophobic 
particles might be poorly collected by the impinger’s liquid owing to poor particle 
wettability. The particle “bouncing” phenomenon and reduced collection efficiency is even 
more significant with dry collection models such as impactors (Xu et al., 1993). The 
“bouncing” effect has also been reported to be dependent on formulation, impactor design 
(Mitchell et al., 2003) and angle of particle deposition (Xu et al., 1993).  
 
In this study, we have proposed a convenient, economical, and environment-friendly 
approach to predict the stability of liposomes during nebulization without conducting 
aerosolization studies. This was achieved by performing excessive extrusion through 
polycarbonate membrane filters. The repetitive shearing provided by extrusion (51 cycles 
through 1 µm pore filters) aimed to simulate that occurring during nebulization. The 
extrusion approach was evaluated using salbutamol sulphate (SBS) and beclometasone 
dipropionate (BDP) as vesicle-entrapped hydrophilic and hydrophobic drugs respectively. 
Drug retention by liposomes upon extrusion was assessed as a stability indicator, using 
cholesterol as “rigidity” enhancer (Kirby et al., 1980) and Tween 80 as “fluidity” promoter 
(Young et al., 1983) of the vesicles. Vesicles made using Tween 80 were referred to as 
“surfactosomes” and were compared to conventional liposomes. The findings of extrusion 
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studies were appraised in relation to a range of liposome nebulization studies available in 
the literature.  
 
2. Materials and methods 
 
2.1. Materials 
Soya phosphatidylcholine (SPC; Lipoid S-100) was a gift from Lipoid, Switzerland. 
Cholesterol, beclometasone dipropionate (BDP) and Tween 80 were purchased from Sigma 
Aldrich, UK. Sodium chloride (ACS, 99.0%), salbutamol sulphate (SBS, 99%), sodium 1-
hexane sulfonate monohydrate (99%) and Triton X-100 were all purchased from Alfa Aesar, 
UK. Glacial acetic acid, chloroform (stabilized with ethanol), water (HPLC-grade) and 
methanol (HPLC-grade) were all supplied by Fisher Scientific, UK. Ferric chloride and 
Ammonium thiocyanate were purchased from VWR, UK, and Deuterium oxide (D2O; 
NMR-grade) was purchased from Acros organics, UK. 
 
2.2. Methods 
 
2.2.1. Preparation of liposomes and surfactosomes 
SPC alone or with cholesterol (1:1 mole ratio) were used to prepare liposomes by dissolving 
the lipids in chloroform (20 mg/ mL) within a round bottomed flask. The organic solvent 
was removed using a rotary evaporator (Büchi Rotavapor R-215, Büchi, Switzerland) under 
vacuum for 1 h in a water bath at 37ºC using the maximum rotation speed (280 rpm). The 
resultant thin lipid film was hydrated by adding SBS dissolved in 1 mL NaCl (0.9%) 
solution followed by manual shaking. The dispersion was left to anneal for 15 min before 
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further dilution with drug-free NaCl (0.9%) solution, followed by vigorous hand shaking to 
give a lipid concentration of 15 mg/mL, and further annealing was allowed for 2 h at room 
temperature. In other batches, the same procedure was repeated by inclusion of BDP in the 
lipid phase (2.5 mole% of lipid) and the same hydration procedure was followed, using D2O 
for hydration. Surfactosomes were prepared by using SPC with or without cholesterol (1:1 
mole ratio) with Tween 80 (15% w/w of total lipid). The lipid and surfactant were dissolved 
in chloroform in a round-bottomed flask to give a lipid concentration of 20 mg/mL. 
Following organic solvent removal, the thin film was hydrated as described above using 
either SBS (15mg/mL; added with the aqueous phase) or BDP (2.5 mole% incorporated into 
the lipid phase).  
 
2.2.2. Extrusion of formulations 
Avestin Liposofast Mini-extruder (GC technologies, UK) was employed to extrude 
liposomes or surfactosomes using Nucleopore Track-etched polycarbonate membrane filters 
with pore sizes: 5 µm (11 cycles), 2 µm (11 cycles), 1 µm (7 cycles) and 0.4 µm (7 cycles) 
(Nucleopore, UK). The number of cycles was chosen based on preliminary optimization 
experiments to ensure the desired vesicle size was achieved. 
 
2.2.3. Vesicle size analysis 
The size distribution of liposomes and surfactosomes was determined by laser diffraction 
(Malvern Mastersizer 2000, Malvern Instruments Ltd, UK) with the polydisperse mode of 
analysis. Volume median diameter (VMD; 50% undersize) and Span were recorded. Span is 
a term, used by Malvern Instrument software to express the polydispersity of particles. 
Mathematically, Span = (90% undersize – 10% undersize) / VMD.  
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2.2.4. Determination of SBS entrapment in liposomes and surfactosomes 
Vesicle-entrapped SBS was separated from unentrapped drug by centrifugation (Beckman 
ultracentrifuge, L8-80M, USA) at 55,000 rpm for 35 min at 6°C. The supernatant was 
collected to quantify the unentrapped (free) drug. Triton X-100 solution was added to the 
pellet of liposomes or surfactosomes to disrupt the vesicles and release the entrapped drug 
for quantification via HPLC. The mobile phase comprised an aqueous solution of sodium 1- 
hexane sulfonate (5 mM) and methanol (75:25 v/v) with glacial acetic acid added to 
constitute 1% of the total mobile phase volume. The Agilent 1200 HPLC instrument 
(Agilent, USA) was set up using a C18 column (Eclipse XDB-C18, 4.6 x 150 mm, Agilent, 
UK) with mobile phase flow rate 1 mL/min. The temperature was set at 40ºC and UV 
wavelength at 276 nm (Elhissi et al., 2006a). 
 
2.2.5. Determination of BDP entrapment in liposomes and surfactosomes 
Deuterium oxide (D2O; density = 1.053 g/mL) was used to separate entrapped and 
unentrapped BDP, by adapting the method of Batavia et al. (2001). Vesicles containing BDP 
were separated from free BDP crystals by centrifugation using D2O as dispersion medium. 
The sample was centrifuged within Eppendorf tubes at 13,000 rpm (relative centrifugal 
force: 15,300 x g) for 90 min at room temperature using a bench-top centrifuge (Jencons-
PLS, Spectrafuge 24D, Jencons Scientific Ltd., UK). Following centrifugation, the floating 
“creamy” layer comprised the lipid vesicles (and entrapped drug), was aspirated and 
dissolved using methanol to release entrapped BDP for quantification by HPLC. 
Centrifugation caused BDP crystals to sediment in the bottom of the tubes. The supernatant 
was separated, and the sedimented BDP was dissolved in methanol and aspirated for 
quantification of unentrapped drug using HPLC. Methanol and water (3:1 v/v) constituted 
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the mobile phase, and the flow rate was set at 2 mL/min with a sample injection volume of 
50 µL and UV detection at 238 nm (Nasr et al., 2014).  
 
2.2.6. Validation of separation of entrapped BDP using phospholipid assay and light 
microscopy 
To ensure that separation of entrapped BDP via centrifugation using D2O was effective, 
phospholipid was quantified in the floating layer, the sedimented spot, and the aqueous 
phase between the sediment and the floating layer, using the Stewart assay (Stewart, 1980)  
following the method designed by Elhissi and Taylor (2005). Liposome samples were 
placed into glass centrifuge tubes and ethanol was added to dissolve the liposomes. The 
solution was placed in an oven overnight to evaporate the ethanol and yield a dry lipid film. 
Chloroform (2 mL) was added followed by addition of an equal volume of ammonium 
ferrothiocyanate solution (prepared by dissolving 6.76 g ferric chloride and 7.6 g 
ammonium thiocyanate in deionized water made up to 250 ml with water). The tubes were 
vortexed for 20 s and centrifuged at 4,000 rpm for 10 min at 4ºC using a bench centrifuge 
(Jouan B4i, Thermo Electron Corporation, UK). The chloroformic layer was separated and 
the concentration of phospholipid was estimated at 485 nm using the Jenway 7315 
Spectrophotometer (Jenway, France). The rotation speed used for separation was chosen 
following extensive optimization aiming to ensure absence of phospholipid in the sediment 
and absence of BDP crystals in the floating layer. The sedimented material following 
centrifugation appeared as a spot at the bottom of the tube and was dispersed in deionized 
water followed by performing light microscopy (Novex B-series microscope, Euromex, The 
Netherlands) to investigate whether centrifugation using D2O was effective for separation of 
unentrapped BDP crystals from liposome-entrapped drug.  
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2.2.7. Stability of liposomes and surfactosomes on excessive extrusion  
Liposomes and surfactosomes, with or without cholesterol, were centrifuged using a bench 
centrifuge and the vesicles (containing the entrapped fraction of SBS or BDP) were 
separated (using the separation methods described above). The freshly prepared (i.e. 
unextruded) vesicles were collected following centrifugation and re-suspended in fresh 
drug-free aqueous phase (deionized water for SBS formulations and D2O for BDP 
preparations) to have a theoretically estimated drug entrapment efficiency of 100%. The 
vesicles were then extruded 51 times through 1 µm polycarbonate membranes. After 
extrusion, the drug entrapped in the vesicles was analysed using HPLC. The extruded 
liposomes or surfactosomes were again centrifuged and the medium containing the 
unentrapped drug was replaced with a drug-free medium. These 1µm vesicles, with 
theoretical 100% drug entrapment efficiency were further extruded 51 times through the 
same pores size filters, and the drug entrapment was again determined. This experiment was 
conducted to study the difference in drug retention between un-extruded (freshly prepared) 
and extruded (1 µm) vesicles using excessive extrusion (51 cycles). We have found that, 
regardless of formulation, 17 cycles of extrusion were sufficient to cause extensive 
disruption to liposomes and leakage of the originally entrapped drug (data not shown). In 
the present study, this number of extrusion cycles was tripled (i.e. using 51 cycles) to ensure 
that liposomes were massively disrupted, as would happen during nebulization.    
 
2.2.8. Saturation solubility of BDP in presence of Tween 80  
To determine the solubility of BDP in water, excess BDP was added to 1 mL water within 
an Eppendorf tube. The contents were mixed in a water bath for 24 h at 40°C. The 
Eppendorf tube was centrifuged for 20 min and the supernatant was tested for drug 
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concentration using HPLC. The same procedure was repeated to analyse the solubility of 
BDP in the presence of Tween 80 in water (15:85 v/v).  
 
2.2.9. Statistical analysis 
All experiments were conducted three times using three different batches, and the resultant 
data were analysed using the SPSS statistical program (IBM Corporation, New York, USA). 
Data were presented as mean ± standard deviation (SD). The difference between groups was 
regarded to be statistically significant when p value was lower than 0.05 using student t-tests 
or analysis of variance (ANOVA) to compare two groups or more than two groups 
respectively. 
 
3. Results and discussion 
 
3.1. Entrapment of SBS in liposomes and surfactosomes prior to extrusion 
SBS entrapment in unextruded liposome and surfactosome vesicles was higher (p˂0.05) 
when cholesterol was included (Table 1). The low entrapment of hydrophilic drugs in 
liposomes can be attributed to the limited aqueous space within the vesicles, with the 
majority of the drug molecules present in the continuous phase of the dispersion (Taylor et 
al., 1990a, Shivhare et al., 2012). The entrapment values obtained were higher than those 
found in other studies for the same drug using the thin film hydration method (Elhissi et al., 
2006a), which might be attributable to the two-step hydration protocol adopted in the 
present study. Cholesterol confers rigidity to liposome bilayers, reducing drug leakage and 
enhancing liposome stability (Kirby et al., 1980) and its inclusion in bilayers has been 
reported to increase the entrapment of hydrophilic drugs (Taylor et al., 1990a). Moreover, 
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the entrapment values for SBS in liposomes might be underestimated due to drug leakage 
during centrifugation (Bendas and Tadros, 2007).   
 
3.2. Size of liposomes and surfactosomes before and after extrusion 
To study the influence of shearing on vesicle stability a range of liposome and surfactosome 
formulations with defined particle sizes were prepared by extrusion. The appropriate 
number of extrusion cycles was determined in preliminary experiments (data not shown) to 
achieve the desired VMD (i.e. when median vesicle size is very similar to the pore size of 
the membrane pores). For each membrane pore size, the number of extrusion cycles which 
gave minimum Span and desired VMD was identified and used in subsequent studies. Since 
cholesterol maximizes vesicle stability and minimizes drug leakage during nebulization 
(Taylor et al., 1990b), liposomes prepared from SPC and cholesterol (1:1) were used to 
determine the number of extrusion cycles required. Thus, extrusion via 5 and 2 µm 
membrane filters was performed 11 times while extrusion through the 1 and 0.4 µm filters 
was conducted 7 times.  
 
Figure 1 shows the VMD (i.e. median size) and Span (i.e. size distribution) upon extrusion 
of SPC liposomes (liposomes without cholesterol), SPC:Chol (1:1) (liposomes with 
cholesterol), surfactant-enriched SPC vesicles (surfactosomes without cholesterol), and 
surfactant-enriched SPC:Chol (1:1) (surfactosomes with cholesterol). Unextruded vesicles 
had large VMD and relatively high Span values, indicating that vesicles at this stage had 
high polydispersity. For unextruded vesicles, liposomes with cholesterol were larger 
(p˂0.05) than surfactosomes with or without cholesterol. Extrusion through 5 µm membrane 
filters generally resulted in significant reduction in VMD and Span of liposomes and 
surfactosomes. The VMDs of liposomes and surfactosomes extruded through 5 µm 
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membranes were smaller than the pore size of the membrane used, possibly because of the 
presence of large populations of vesicles below 5 µm in the samples prior to extrusion. 
Subsequent extrusion of liposomes and surfactosomes through 2, 1 and 0.4 µm membranes 
produced vesicles with size similar to that of the filter pores (Fig. 1a), and the Span values 
were also lower (Figure 1b), indicating that smaller pore size made the vesicles smaller and 
more homogeneous. It was found that the Span values were reduced significantly when 
vesicles were extruded through 0.4µm membrane as compared to un-extruded vesicles 
(p<0.05). These findings show that extrusion as a means of generating vesicles of uniform 
size distribution is applicable not only using conventional liposomes, which is established in 
literature (Olson et al., 1979; Hope et al., 1986), but also with surfactosomes used in the 
present investigation.  
 
3.3. SBS retention in extruded liposomes and surfactosomes 
Unentrapped drug (i.e. in continuous phase) was removed by centrifugation and aqueous 
phase was replaced with drug-free water, to make drug entrapment efficiency having a 
theoretical estimate of 100%. Thus, extrusion through each membrane was undertaken with 
vesicles having a theoretical 100% SBS entrapment efficiency. However, before performing 
the extrusion cycles, experimental determination of drug entrapment efficiency gave values 
of less than 100%, indicating drug was partially lost from vesicles via the burst effect during 
the time taken for practical estimation of values (Figure 2). For surfactosomes, almost 50% 
of the originally entrapped drug was lost from cholesterol-containing surfactosomes, and the 
loss was even greater from cholesterol-free vesicles (Figure 2), indicating that Tween 80 has 
made the vesicles very leaky (Young et al., 1983) even when no extrusion was performed. 
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Compared to extrusion through relatively large pore filters (e.g. 1-5 µm), extrusion through 
smaller membrane pores (e.g. 0.4 µm) caused marked loss of the originally entrapped SBS 
(i.e. drug retention decreased). In a previous investigation, we studied the influence of 
vibrating-mesh nebulization on the stability of liposomes and vesicle retention of SBS. 
Customized nebulizers with large mesh apertures (8 µm) helped reduce drug loss during 
nebulization compared to devices having conventional 4µm apertures (Elhissi et al., 2006a; 
Elhissi et al., 2007), indicating correlation of membrane extrusion findings with previous 
vibrating-mesh nebulization studies. The membrane extrusion findings presented here 
correlate with previous vibrating-mesh and jet-nebulizer studies; greater drug loss occurs 
from liposomes forced through the smaller pores as the greater shearing forces are applied to 
the vesicles. In jet-nebulizers, the shearing force can be increased by increasing the flow rate 
of gas used to convert the nebulizer fluid into aerosols (O’Callaghan and Barry, 1997). 
Niven and co-workers (1992) have studied the influence of increased jet nebulizer shearing 
on liposome stability by increasing the flow rate of gas employed to convert liposomes into 
aerosol. They demonstrated that liposomes exhibited an air pressure-dependent leakage of 
the originally entrapped hydrophilic marker, with losses being in the range of 1.3% to 
88.2% using gas flow rates of 2.4 to 11.1 L/min respectively (Niven et al., 1992). 
 
Liposomes and surfactosomes containing cholesterol exhibited lower drug loss (i.e. highest 
drug retention) on extrusion, than those without, including vesicles extruded through 0.4µm 
pore membranes (Figure 2). Previous studies have shown that cholesterol produced a 
protective effect, helping phosphatidylcholine vesicles withstand shear stresses provided by 
magnetic field (Tseng et al., 2007) or jet-nebulization (Taylor et al., 1991; Bridges and 
Taylor, 2000), indicating a correlation of these extrusion findings with previous 
aerosolization studies. The liposomal formulation of Amikacin (Arikace®) is currently in 
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advanced stages of development and is actually enriched with cholesterol as bilayer 
composition (Cipolla et al., 2013; Ehsan et al., 2014), further highlighting the importance of 
cholesterol in nebulizable liposome formulations. 
 
Drug loss was greater for vesicles enriched with surfactant (i.e. surfactosomes) even prior to 
extrusion (Figure 2), demonstrating that bilayers have become more permeable and/or 
susceptible to damage during shearing, as a result of surfactant inclusion in the formulation. 
Lehofer and co-workers (2014) have reported greater losses from PEGylated liposomes 
during nebulization when compared to conventional cholesterol-enriched vesicles, 
indicating the PEG polymer has interfered with the integrity of the liposome bilayers. 
Differential scanning calorimetry studies on liposomes have shown that amphiphilic 
materials can interfere with liposome stability by inducing phase separation in the bilayers 
and changing the packing patterns of the phospholipid molecules (Castile et al., 1999; 
Castile et al., 2001; Tasi et al., 2003). These findings indicate that surfactants included with 
the aim of promoting the “ultradeformability” of liposomes to enhance vesicle stability may 
actually interfere with the integrity of the bilayers and promote drug leakage from the 
vesicles (Elhissi et al., 2012). For this reason, our surfactant-enriched liposomes were 
referred to as “surfactosomes” rather than “ultradeformable” liposomes which are 
commonly used for enhancing transdermal drug delivery (Verma et al., 2003; Dubey et al., 
2006; Subongkot et al., 2014). 
 
3.4. Stability of SBS-entrapped liposomes and surfactosomes using excessive extrusion 
Large liposomes are “processed” during air-jet or vibrating-mesh nebulization, as they are 
exposed to excessive, repeated shearing and undergo size reduction to gain the optimum size 
for delivery from the nebulizer (i.e. to be incorporated into the generated aerosol droplets) 
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(Elhissi and Taylor, 2005; Kleemann et al., 2007). In jet-nebulizers, the reservoir contents 
undergo extensive shearing before being released in fine aerosol droplets for inhalation 
(O’Callaghan and Barry, 1997; Kleemann et al., 2007).   
 
Niven and co-workers (1991) showed that that extent of soluble material loss from 
liposomes was dependent on the duration of nebulization, with longer processing within the 
nebulizer causing multiple times of shearing cycles within the nebulizer reservoir, and 
subsequently greater vesicle damage and drug losses. In an attempt to simulate these 
shearing conditions, we have designed an excessive shearing procedure by subjecting 
freshly prepared non-extruded (i.e. large) liposomes and surfactosomes to 51 cycles of 
extrusion through 1 µm membrane filters, followed by studying SBS entrapment in the 
vesicles. In order to investigate whether the resultant extruded vesicles (1 µm diameter) 
would retain the drug upon applying further shearing, the unentrapped drug, as a result of 
extrusion damage was removed and replaced with drug-free deionized water and further 51 
cycles of extrusion through the same size filter was conducted, followed by determination of 
the drug entrapment (Table 2).  
 
Following extrusion 51 times through 1µm polycarbonate membrane filters, liposomes or 
surfactosomes containing cholesterol retained significantly greater SBS proportions than 
cholesterol-free formulations (Table 2; p<0.05), with liposomes retaining markedly greater 
drug proportions than surfactosomes (p<0.05). When the extruded vesicles, after separation 
of the unentrapped drug (i.e. to theoretically yield 100% drug entrapment efficiency) were 
further extruded through 1µm membranes, further SBS loss occurred, but drug retention was 
significantly higher that observed with the large vesicles (Table 2). This clearly indicates 
that smaller liposomes had greater ability to retain entrapped hydrophilic materials 
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compared to large liposomes (Table 2), agreeing with nebulization studies of liposomes 
(Taylor et al., 1990; Niven et al., 1991; Elhissi et al., 2007; Kleemann et al., 2007; Lee et al., 
2013).   
 
Table 2 indicated that the influence of extrusion on drug retention was mainly affected by 
two factors, namely vesicle size and bilayer composition. For surfactosomes, the inclusion 
of cholesterol and using small vesicles (1µm) were needed to minimize drug losses, whilst 
for liposomes cholesterol inclusion was more important at minimizing the loss of entrapped 
SBS; this justifies the use of cholesterol in the liposomal formulation of the hydrophilic 
antibiotic amikacin (Arikace®) (Cipolla et al., 2013). Regardless of bilayer composition and 
vesicle size, surfactosomes exhibited lower retention for SBS (Table 2). Surfactant-enriched 
vesicles were found to be very unstable during nebulization, regardless of aerosolization 
mechanism, causing extensive losses of the hydrophilic drug SBS (Elhissi et al., 2012). This 
suggests that the use of extensive membrane extrusion, introduced in this study, has 
applicability in predicting vesicle stability during nebulization.  
 
3.5. Entrapment of BDP by liposomes and surfactosomes prior to extrusion 
Whilst vesicle shearing within nebulizers may cause loss of liposome-entrapped 
hydrophobic drugs, this generally occurs to a much lesser extent compared to hydrophilic 
materials (Desai et al., 2002). Determination of BDP entrapment in liposomes and 
surfactosomes requires reliable separation of the unentrapped drug from the vesicle-
entrapped BDP. BDP tends to form crystals during centrifugation in aqueous media, usually 
resulting in simultaneous sedimentation of the BDP-entrapping vesicles and the free drug 
crystals (Batavia et al., 2001; Khan et al., 2015). However, concomitant sedimentation of 
drug crystals and liposomes did not occur when vesicles were dispersed in high density 
18 
 
water (i.e. deuterium oxide; D2O) (Batavia et al., 2001; Khan et al., 205); thus in the present 
work, the thin lipid films containing BDP were hydrated with D2O instead of deionized 
water.  
 
As demonstrated in Figure 3, by using D2O and an optimum centrifugation speed, BDP 
crystals were sedimented while liposomes containing incorporated drug constituted a 
floating creamy layer. Some dissolved BDP might be present in the middle region of the 
centrifugation tube (i.e. between the floating liposomes and BDP sediment), and this 
fraction was considered with the sedimented fraction of the drug as the total proportion of 
unentrapped steroid (Figure 3). The sedimented crystals appeared as a “spot” at the bottom 
of the tube; this fraction was ascertained to be BDP analytically using HPLC and visually 
using light microscopy (Figure 4). Light microscopy also confirmed that the floating layer 
comprised liposomes (Figure 4). The Stewart phospholipid assay (Stewart, 1980) indicated 
that the sediment contained negligible phospholipid, confirming successful separation of the 
vesicle-entrapped drug from the free BDP crystals. BDP tends to crystallize during storage 
due the incompatible steric fit between the steroid and the liposome bilayers, restricting 
incorporation of this drug into liposomes (Batavia et al., 2001), though BDP interaction with 
bilayers is highly dependent on the excipients used, and the liposome preparation method 
employed (Elhissi et al., 2006b). 
 
Figure 5 shows the proportion of lipid in each layer of the centrifuged cholesterol-
containing liposomes and surfactosomes. The amount of lipid in the top layer was 
considerably greater than that in the middle layer and sedimented material (Figure 5), 
indicating that separation of BDP-entrapping liposomes from free BDP was successful and 
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agreeing with our recent findings using a slurry method to prepare liposomes from 
proliposome powders (Khan et al., 2015).  
 
BDP entrapment was determined using HPLC (Table 3). Drug entrapment and loading were 
dependent on formulation, and inclusion of cholesterol has enhanced the drug entrapment 
(p˂0.05; Table 3). The limited entrapment of BDP in phospholipid vesicles (Table 3) has 
been reported in a range of previous investigations (Fildes and Oliver, 1978; Batavia et al., 
2001; Darwis and Kellaway, 2001). When liposomes were compared with surfactosomes, 
Table 3 has shown that BDP entrapment was influenced by cholesterol (p˂0.05) whilst 
Tween 80 had no effect (p>0.05) on the steroid entrapment.  
 
3.6. BDP incorporation and retention in extruded liposomes and surfactosomes 
Liposomes and surfactosomes were separated from the dispersion medium by 
centrifugation, then re-suspended in drug-free D2O to make the theoretical entrapment 
efficiency of the drug 100%. On extrusion,  as the pore size of polycarbonate membrane was 
reduced, drug entrapment decreased, with greatest loss occurred when vesicles were 
extruded through 0.4 µm membranes (p<0.05) (Figure 6). The reduction in entrapment of 
BDP as a result of extrusion (Figure 6) was less than that of SBS (Figure 2). Liposomes with 
cholesterol retained significantly more BDP than those without cholesterol (p<0.05). 
Conversely, cholesterol did not significantly affect drug retention in surfactosomes during 
extrusion, regardless of filter pore size (p>0.05). Following extrusion of cholesterol-
containing vesicles, it can be generally seen that the entrapment efficiency of BDP in 
liposomes and surfactosomes was not greatly different (Figure 6).  
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When cholesterol was included in the formulations prior to extrusion, liposomes tended to 
provide higher BDP retention compared to cholesterol-free liposomes. By contrast, 
inclusion of cholesterol in surfactosome formulations did not enhance the retention of BDP 
during extrusion (Figure 6). We hypothesise here that cholesterol might have displaced a 
fraction of Tween 80 molecules from the bilayers to the continuous phase. The free 
surfactant molecules have possibly solubilized some BDP in the continuous phase, causing 
less entrapment of the steroid in the bilayers. To investigate whether this hypothesis is valid, 
a simple solubility study of BDP in Tween 80 solution versus solubility in pure deionized 
water was conducted. In presence of Tween 80, greater quantities of BDP became soluble 
(Table 4). This possibly means that formulations with surfactosomes had greater proportions 
of BDP solubilized in the continuous phase by the free surfactant molecules, hence, less 
incorporation of BDP in the lipid bilayers of surfactosomes has occurred. Whilst some 
investigators have reported lower drug entrapment in the bilayers as a result of enhancing 
fluidity of liposome membranes (Young et al., 1983), other reports have demonstrated 
enhanced entrapment of hydrophobic drugs (e.g. BDP) when liposomes with more fluid 
membranes were prepared (Darwis and Kellaway, 2001).      
 
3.7  Stability of BDP-entrapped liposomes and surfactosomes using excessive extrusion 
Freshly prepared BDP formulations (i.e. unextruded liposomes) were extruded 51 times 
through 1 µm polycarbonate membrane filters. Vesicles containing cholesterol retained 
significantly greater BDP proportions than those without cholesterol (p<0.05; Table 5). 
Earlier in this study cholesterol did not improve the retention of BDP in surfactosomes using 
the normal extrusion procedure (Figure 6), leading to the hypothesis that cholesterol has 
displaced Tween 80 from the bilayers, leading to enhanced steroid solubility in the 
continuous phase and reduced drug incorporation into the bilayers. However, the findings 
21 
 
with excessive extrusion were different since cholesterol significantly enhanced BDP 
retention in surfactosomes (p˂0.05; Table 5). It is possible that excessive extrusion and 
repetitive shearing have enhanced the intermixing of phospholipid with Tween 80, hence 
reducing the proportion of the free surfactant in the continuous phase and enhancing BDP 
retention in the bilayers. Further studies are needed to evaluate the influence of cholesterol 
on the stability of surfactant-enriched phospholipid vesicles.   
 
After separation of the unentrapped drug from the 1 µm vesicles and replacing that with 
drug-free dispersion medium (i.e. to reach a theoretical entrapment of 100%), the vesicles 
were again extruded 51 times through 1µm polycarbonate membranes. In this case, BDP 
retention was greater than values obtained upon extruding the freshly prepared vesicles. 
Moreover, when the small size vesicles were extruded the advantage of cholesterol at 
retaining greater BDP proportions was diminished, especially for liposomes (Table 5). 
Excessive jet-nebulizer shearing of BDP-liposomes made with different lipid compositions 
did not compromise the controlled release property of the formulations inhaled by healthy 
volunteers (Saari et al., 1999). This correlates well with findings employing high sensitivity 
differential scanning calorimetry to evaluate BDP interaction with the liposome bilayers 
following jet-nebulization; it was found that drug interaction with the bilayers was preserved 
despite the aggressive shearing of liposomes (Elhissi et al., 2011).  
 
To our best knowledge, the present work is the first of its kind that has correlated extrusion 
of liposomes with in vitro and in vivo literature findings of stability of drug-loaded 
nebulized liposomes. The use of polycarbonate membrane extrusion to predict the stability 
of vesicle-based systems to nebulization can save time, reduce cost in the formulation and 
manufacturing development of nebulizable liposomes and minimize potential hazards 
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associated with reduced collection efficiency of liposomal aerosols during nebulization. It is 
important to bear in mind that these experiments employing mini-extruders have been used 
here to predict the general trend of vesicle stability to nebulization, rather than correlating 
with vesicle stability findings using specific nebulizer designs or operating mechanisms. 
Future studies will investigate the possible optimization of extrusion conditions to correlate 
with particular nebulizers operating mechanisms at particular operating conditions. Future 
investigations may also involve large extruders attached to gas cylinders in order to 
investigate the effect of gas flow rate on drug retention in vesicles. The extrusion approach 
introduced here will not eliminate the ultimate need for performing aerosolization studies 
but would rather markedly reduce them, by providing a screening tool for formulations that 
are best candidates for nebulization experiments. 
 
4. Conclusion 
Shearing studies via membrane extrusion have demonstrated greater retention of the 
hydrophobic drug BDP into liposomes and surfactosomes when compared to the hydrophilic 
drug SBS. This correlates with previously reported findings of vesicle stability to 
nebulization-induced shearing published by our research group and several other 
investigators. Hence, membrane extrusion may offer a means for predicting the stability of 
liposomes to aerosolization, avoiding the time consuming procedures of nebulization, and 
minimizing the possibility of laboratory contamination with unsuccessfully collected 
aerosols during development of nebulizable liposome formulations. Currently, Arikace® and 
PulmaquinTM are in late stage development and further  nebulizable liposome formulations 
are in the pipeline. We expect future development of inhalable liposomes to benefit from 
this study and consider extrusion as a tool for predicting liposome stability to nebulization.   
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Figure 1. VMD (a)  and span (b) of liposomes and surfactosomes prepared with or 
without cholesterol, and with or without extrusion through 5, 2, 1 or 0.4 µm 
polycarbonate membrane filters (n = 3 ± SD) 
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Figure. 2. SBS retention in liposomes and surfactosomes with or without 
cholesterol, before or after passing the vesicles through polycarbonate 
membrane filters of pore size 5, 2, 1 or 0.4 µm (n=3 ± SD) 
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Figure 3. Eppendorf tube following centrifugation of liposomes in D2O medium. 
Three regions were apparent: the upper floating layer ( liposomes with 
entrapped drug), the sediment (free BDP crystals) and middle region (D2O-
soluble fraction of BDP) 
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Figure 4. Light microscopy images for samples collected from the 
floating creamy layer (a) and the sedimented material (b). Samples 
revealed that the creamy layer constituted of liposomes whilst the 
sediment was mainly BDP crystals. The samples were typical of 3 
different experiments 
(a) 
(b) 
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Figure 5. Phospholipid content in the three regions, following centrifugation of  
cholesterol-containing liposome and surfactosome BDP preparations (n=3 
±SD) 
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Figure. 6. BDP entrapment in liposomes and surfactosomes, with or without 
cholesterol, before extrusion or after passing through polycarbonate membrane 
filters of pore size 5, 2, 1 or 0.4 µm (n=3 ± SD) 
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Table 1. Entrapment efficiency and loading of SBS in unextruded liposomes 
and surfactosomes, as determined by HPLC (n = 3 ± sd) 
Formulation 
Entrapment 
efficiency 
(%) 
Drug loading 
(mg drug/100 
mg lipid)  
Liposomes with cholesterol 30.03 ± 1.69 2.00 ± 0.11 
Liposomes without cholesterol 23.25 ± 0.75 1.55 ± 0.05 
Surfactosomes with cholesterol 29.7 ± 7.26 1.98 ± 0.48 
Surfactosomes without cholesterol 21.36 ± 5.5 1.42 ± 0.37 
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Table 2. Stability of SBS liposomes and surfactosomes using excessive extrusion 
through 1µm polycarbonate membrane (n = 3 ±sd) 
Formulation SBS retention after 51  
extrusion cycles of large 
freshly prepared vesicles 
through 1 µm membrane 
pores (%) 
SBS retention  after 
further 51 extrusion 
cycles of previously 
extruded vesicles through 
1 µm membrane pores 
(%) 
Liposomes with 
cholesterol 
60.10  ±  3.67 67.27  ±  1.86 
Liposomes without 
cholesterol 
45.06  ±  2.95 63.77  ±  1.65 
Surfactosomes with 
cholesterol 
14.60  ±  1.04 52.00  ±  1.17 
Surfactosomes without 
cholesterol 
6.60  ±  0.98 47.9  ±  3.30 
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Table 3. Entrapment efficiency and loading of BDP in unextruded liposomes 
and surfactosomes, as determined by HPLC (n = 3 ± sd)  
Formulation 
Entrapment 
efficiency (%) 
Drug loading (mg 
drug/100 mg lipid) 
Liposomes with cholesterol 31.66 ± 3.05 2.10 ± 0.20 
Liposomes without 
cholesterol 
24.66 ± 2.82 1.64 ± 0.23 
Surfactosomes with 
cholesterol 
30.66 ± 3.21 2.04 ± 0.21 
Surfactosomes without 
cholesterol 
22.66 ± 4.72 1.5 ± 0.31 
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Table 4. Solubility of BDP in water and Tween 80 solution (n = 3 ± sd) 
 
Medium Saturated solubility of BDP 
Deionized water 0.14  µg/ml 
Tween 80 aqueous solution 12.67 µg/ml 
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Table 5. Stability of BDP liposomes and surfactosomes using excessive extrusion 
through 1µm polycarbonate membrane (n = 3 ±sd) 
 
Formulation BDP retention after 51  
extrusion cycles of 
large freshly prepared 
vesicles through 1µm 
membrane pores (%) 
BDP retention  after 51 
further extrusion cycles 
of previously extruded 
vesicles through 1µm 
membrane pores (%) 
Liposomes with cholesterol 65.8  ± 1.79 87.13  ±  1.8 
Liposomes without cholesterol 55.27  ± 2.97 84.10  ±  1.10 
Surfactosomes with cholesterol 55.30  ±  3.08 78.47  ±  1.45 
Surfactosomes without 
cholesterol 
49.50  ±  2.36 71.03  ± 2.15 
 
 
 
